Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ANVS with free AI briefings, catalyst countdowns, and dilution alerts.

ANVS · Annovis Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.8M Cash on Hand
0.4mo Cash Runway
Follow ANVS by email Get an email when ANVS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ANVS, unsubscribe in one click. Privacy

📣 What ANVS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Buntanetap Parkinson's Disease (PD) Phase 2/3 · NCT07284784 Recruiting
posiphen Alzheimer's Disease Phase 1/2 · NCT02925650 Completed
Posiphen® tartrate capsules Alzheimer's Disease Phase 1 · NCT01072812 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ANVS holds $2.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $19M/quarter from operations, an estimated runway of 0.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANVS files for a raise →

👥 Who Owns ANVS

Insiders 15.9% Institutions (69 holders) 15.5% Public and other holders 68.6%
HolderTypeShares% of sharesAs of
Michael B Hoffman
Director · +5.03M options
Insider 8,588,240 13.85% 2026-11-06
Highbridge Capital Management, LLC Institution (13G, 5%+) 2,775,578 4.48% 2026-06-30
Maria-Luisa Maccecchini
President & CEO, Director · +108,800 options
Insider 1,212,020 1.95% 2025-10-28
Mark K. White
Director · +48,346 options
Insider 61,167 0.10% 2023-11-20
Claudine Bruck
Director · +26,200 options
Insider 13,709 0.02% 2025-09-10
Reid McCarthy
Director · +29,600 options
Insider 9,305 0.02% 2025-06-10
Henry III Hagopian
Chief Financial Officer
Insider 1,820 0.00% 2023-11-20
Andrew Walsh
Vice President, Finance
Insider 500 0.00% 2025-06-16

Share count 62,022,520 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ANVS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANVS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.